How much revenue does Immuneonco-b make?

Immuneonco-b reported 154.29 million CNY in revenue for fiscal year 2025, up 108.1% from 74.15 million CNY in fiscal year 2024.

Where does Immuneonco-b make most of its revenue?

United States of America: 100% of revenue by region in fiscal year 2024, followed by PRC (under 1%).

What companies are similar to Immuneonco-b?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Alphamab Oncology (9966.HK), Lepu Biopharma Co., Ltd. (2157.HK), Jacobio-b (1167.HK), Sunho Biologics, Inc. (2898.HK).

Immuneonco-b (1541.HK) Stock

About Immuneonco-b

ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, engages in the research and development of immuno-oncology therapies in China and the United States. The company's core product candidate is IMM01, which is in Phase Ib/IIa clinical trial to evaluate the combination with bortezomib and dexamethasone for the treatment of multiple myeloma; Phase II clinical trial in combination ...

At a glance

Immuneonco-b reported revenue of 154.29 million CNY for fiscal year 2025, up 108.1% from fiscal year 2024, and net income of -218.58 million CNY. United States of America was its largest region in fiscal year 2024, with 100% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.